Corilagin

Description: Corilagin has anti-inflammatory activity. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro.Corilagin can enhance the cytotoxicity of both cisplatin and doxorubicin on the Hep3B hepatoma cells.Corilagin has antiviral activity, reduces the cytotoxicity induced by EV71 or CA16 on Vero cells with and IC50 value of 5.6 and 32.33 µg/mL, respectively. Corilagin shows the potential to protect against HSV-1-induced encephalitis, and the beneficial effects may be mediated by inhibiting TLR2 signaling pathways.Corilagin has antifibrotics property and is potentiated in treating idiopathic pulmonary fibrosis(IPF), attenuates bleomycin-induced epithelial injury and fibrosis via inactivation of oxidative stress, proinflammatory cytokine release and NF-kappaB and TGF-beta1 signaling. Solvent:Pyridine, Methanol, Ethanol, etc. Target: Autophagy, TLR, Reverse Transcriptase, Antibacterial, Apoptosis. Smiles: O[C@H]1[C@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(O)c(O)c(O)cc3C(=O)O[C@H]1[C@H](O)[C@H](OC(=O)c1cc(O)c(O)c(O)c1)O2. References: Wang Z,et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury.